Our previous studies on the rescue of a comprehensive panel encompassing 25 frequent p53 mutations, alongside 800 common cancer-associated p53 mutations, as well as our present investigation, consistently illustrate the modest or negligible potency of ATO in rescuing Y220C [20, 31]. The gene discussed is TP53; the disease is cancer.